Should You Take Urolithin A or Just Eat Pomegranates?
For most people, pomegranate juice makes very little urolithin A. In a 2021 study of 100 adults, only about 40% made a meaningful amount after a glass. If you want a known dose every day, a supplement is the more dependable route. Pomegranates still supply their own compounds, but they are a weak way to hit a specific amount.
The short answer
- Verdict: Pomegranates are an unreliable source. Matching one 500 mg dose of urolithin A would take about six glasses of juice (roughly 1.5 liters) on average.
- First qualifier: Your gut bacteria decide who converts at all. In a 2021 study of 100 adults, about 40% made a meaningful amount after one glass of juice.
- Second qualifier: Researchers disagree on whether age matters. One cohort of 839 people (Cortés-Martín et al., 2018) says aging is the main factor, while the 2021 study found no significant effect.
- Check this: Look for urolithin A in milligrams on the label. The pomegranate juice tested in 2021 had no detectable urolithin A.
Urolithin A is made in your gut, not picked up from fruit, and the pomegranate juice tested in the 2021 study contained none. Ellagitannins in pomegranates, walnuts, pecans and some berries break down to ellagic acid in the upper gut. Gut bacteria in the large intestine then turn ellagic acid into urolithins, and urolithin A is among the most common of them. The ingredient guide explains the compound, and the full urolithin A guide covers the wider picture. This page answers one decision: take the supplement, or rely on food.
Why isn't the answer simple?
Researchers sort people into urolithin metabotypes, the pattern of urolithins a person's gut makes. Age is where the sources split. Cortés-Martín and colleagues studied 839 people aged 5 to 90 and concluded that aging is the main factor shaping the gut bacteria behind metabotype. The 2021 study, with 100 adults aged 18 to 80, found no significant effect of age on who made urolithin A. A 2014 letter by Tomás-Barberán and colleagues pooled several human intervention trials and also saw the same three groups regardless of age, sex or body mass index. So one source says age matters and two say it does not. The methods differ too. The 2021 study measured blood levels after one standard glass of juice, a different measurement from the metabotype studies. Until someone reconciles them, treat your own group as unknown.
The shares are not fixed either. Across the trials in the 2014 letter by Tomás-Barberán et al., the group that made urolithin A alone ranged from 25% to 80% of volunteers. The group that also made isourolithin A or urolithin B ranged from 10% to 50%, and the group with none of these urolithins ranged from 5% to 25%. The authors saw the same three groups whatever food source people ate, so the difference seems to lie in the person rather than the fruit.
What does the evidence say?
Charts of the trial data sit on the clinical data page, and the mitophagy page covers how the compound works inside cells. Five human studies bear on this decision, and one more appears in the table. Each entry gives who was studied, the design, what was measured, the result, the main limitation and a grade for the outcome.
Singh et al., 2021, European Journal of Clinical Nutrition (PubMed). Who and how many: 100 healthy adults aged 18 to 80, tested in Chicago, 68 women and 32 men. Design: a randomized, open-label crossover trial, so participants knew what they took. Each person had a 240 mL glass of 100% pomegranate juice and 500 mg of urolithin A powder (the study product was Mitopure), separated by a washout of 8 to 14 days. Measured: urolithin A glucuronide, the main form in blood, which the liver makes by attaching a sugar acid, at 0, 6 and 24 hours. Result: 12% had detectable levels before the juice. At 24 hours after juice, about 40% reached 100 ng/mL or more, 27% had some but less than that, and 33% had none. Over 24 hours, the 500 mg dose delivered more than six times the total exposure of the juice. Limitation: open-label, one site, one juice, and five of the nine authors list Amazentis SA. Grade for conversion and exposure: Preliminary.
Cortés-Martín et al., 2018, Food & Function (DOI). Who and how many: 839 people aged 5 to 90, in an observational cohort. Measured: metabotype across age groups. Result: the authors conclude aging is the main factor. Limitation: the abstract gives no share for each group, and it calls the health consequences potential. Grade for the age claim: Insufficient, because the human data conflict with each other.
Tomás-Barberán et al., 2014, Journal of Agricultural and Food Chemistry, letter (DOI). Who and how many: volunteers from several human intervention trials, with no combined total in the abstract. Design: observational pooling of trials that used walnuts, berries or pomegranate. Measured: which urolithins each person made. Result: the three phenotypes and ranges above, seen whatever food people ate. Phenotype B was more common in volunteers with metabolic syndrome or colorectal cancer, and the authors say whether the pattern signals health benefit or illness risk "deserves further research." Limitation: pooled trials with different designs and wide ranges. Grade for the shares: Preliminary.
Garcia-Mantrana et al., 2019, Nutrients (DOI). Who and how many: 27 healthy adults. Design: they ate 33 g of peeled raw walnuts over three days, and the abstract describes no control group. Measured: gut bacteria and short-chain fatty acids in stool, with metabotype assigned from urine. Result: the bacterial response to walnuts depended on metabotype, and the UM-B group, which also makes isourolithin A or urolithin B, was the most sensitive to the walnut intervention. Short-chain fatty acid output rose. Limitation: three days and 27 people, and the abstract reports gut changes, not urolithin amounts. Grade: Preliminary.
Singh et al., 2022, Cell Reports Medicine (DOI). Who and how many: 88 untrained adults aged 40 to 64, overweight with low aerobic endurance. Design: randomized, double-blind, placebo-controlled, four months, with 500 mg, 1,000 mg or placebo daily. Measured: strength, exercise performance, and blood and muscle markers. Result: hamstring peak torque rose 12% more than placebo at 500 mg (p = 0.027) and 9.8% more at 1,000 mg (p = 0.029). The primary endpoint, peak power output, did not differ from placebo. Limitation: primary endpoint missed, and six of nine authors list Amazentis SA. Grade for strength: Moderate.
The doses these trials tested were 500 mg and 1,000 mg daily. For food, the only figures we could verify come from pomegranate juice, not walnuts or berries.
Which option fits your situation?
Two questions decide most cases: do you want a known amount, and does your gut already convert? The table maps common situations to what the evidence supports.
| Your situation | What the evidence supports | Why |
|---|---|---|
| You want a known amount every day | A supplement labeled in milligrams of urolithin A | In the 2021 study, the 500 mg dose gave more uniform blood levels than juice did. |
| You enjoy pomegranate or walnuts | Keep eating them, but do not count on them for a dose | Over 24 hours, juice delivered less than one-sixth of the exposure from a 500 mg dose, on average. |
| You want to know whether your gut converts | A test would tell you about food, not change your dose | The 2021 team validated a finger-prick method in its own study, and we did not find a consumer test to recommend. |
| You are 65 or older | Expect thin data for your age, and do not assume your conversion | Age had no significant effect in the 2021 study (ages 18 to 80), but Cortés-Martín et al. (2018) say it matters. The one trial we checked in ages 65 to 90 used 1,000 mg daily for four months (Liu et al., 2022, 66 adults, grade: Preliminary). It improved muscle endurance at two months but missed both primary endpoints. |
| You take medication, are pregnant or breastfeeding, or have a chronic condition | Talk to your clinician first | The trials excluded many of these groups (see below). |
Matching one 500 mg dose from juice would take about six glasses. Most people will not keep that up. A test is worth doing only if the result would change what you do, and for most people the dose is the decision that matters.
How should you take it?
Start at 500 mg once a day, the dose in the 2021 and 2022 studies. The dosage research page shows where the dose curve starts to flatten. In the 2022 trial, the 500 mg group gained more hamstring torque than the 1,000 mg group (12% against 9.8%, each compared with placebo). The higher dose did not beat the lower one in that trial.
Give it time. In the 2021 study, blood levels peaked around six hours after the dose. The trials measured strength and endurance at two and four months, so judge it on that timescale, not after a week.
Timing and food are open questions. None of the studies cited here compared a time of day or a meal. The 2021 team mixed its powder into yogurt, but nothing here says food matters, so pick a time you will remember.
Read the label before you buy. Look for urolithin A in milligrams, not pomegranate extract. The buyer's guide compares labels on dose, testing and cost per day.
Keep the pomegranate if you enjoy it, but it cannot stand in for a dose.
When should you stop or ask someone?
Talk to your clinician before you start if you are pregnant, breastfeeding, planning a pregnancy, taking any medication, or living with a chronic condition. The 2021 study excluded women who were pregnant, breastfeeding or planning a pregnancy, people with chronic medical conditions, and anyone who had taken antibiotics in the 30 days before screening. The 2022 trial excluded people with chronic conditions that needed statins, blood thinners, steroid or thyroid medication. In the 2021 study the team logged 26 adverse events after juice and 15 during the powder, and most were mild and resolved. In the 2022 trial, 17 people on placebo, 13 on 500 mg and 15 on 1,000 mg reported at least one adverse event. If something unexpected happens, stop taking it and call your clinician.
Product note
Our Urolithin A 500 mg capsule gives 500 mg of urolithin A once a day, with 60 capsules to a bottle. At $89.99 it works out to about $1.50 a day, checked October 19, 2026. That dose matches the 500 mg used in the 2021 and 2022 studies, but none of the papers cited here tested this capsule, so their results describe the compound, not our product. Urolithin A supports mitophagy, the way cells recycle worn-out mitochondria.† Shop Urolithin A 500 mg
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Next reads
- The full urolithin A guide: the parent page, covering who it is for and what the trials found.
- Urolithin A dosage and diminishing returns: where the dose curve stops paying off.
- Urolithin A buyer's guide: what to check on a label before you buy.
Related reading
The Bottom Line
Pomegranate juice is an unreliable route to urolithin A for most people. If you want a known amount, the 2021 and 2022 studies used 500 mg a day, so start there and read the label for milligrams. Give it two to four months before you judge it, and talk to your clinician first if you are pregnant, breastfeeding, taking medication or living with a chronic condition. Skip the metabotype test unless the result would change your plan.
Related Products
Urolithin A 500 mg – Mitochondrial Renewal & Cellular Energy | 60 Capsules
$89.99
FAQ
What is a urolithin metabotype, and what share of adults fall into each group?
A metabotype is the pattern of urolithins your gut makes from ellagitannins. Tomás-Barberán and colleagues describe three groups: people who make urolithin A alone (25% to 80% of volunteers across the trials they pooled), people who also make isourolithin A or urolithin B (10% to 50%), and people who make none of these (5% to 25%). No single share applies to everyone, because each figure depends on who was studied. The [urolithin A ingredient guide](/ingredients/urolithin-a) covers the wider context.
How much urolithin A do people actually make from pomegranate, walnuts or berries?
The numbers we could verify come from pomegranate juice. In the 2021 study, about 40% of 100 adults reached 100 ng/mL or more of urolithin A glucuronide 24 hours after a 240 mL glass. Over that day, juice delivered less than one-sixth of the exposure from a 500 mg dose, on average. Matching one 500 mg dose would take about six glasses. We did not find a verified urolithin A amount for walnuts or berries, so we do not give one. The walnut study we found tracked gut bacteria, not urolithin amounts.
What did the 2021 exposure study measure, in how many people, and how was it designed?
It measured urolithin A glucuronide, the main form in blood, at 0, 6 and 24 hours. Of 136 people screened, 100 healthy adults aged 18 to 80 were randomized into a crossover trial. Each person had a glass of 100% pomegranate juice and a 500 mg urolithin A powder, with a washout of 8 to 14 days between them. The design was open-label, so participants knew what they took. Five of the nine authors list Amazentis SA. For how the compound works inside cells, see the [mitophagy research page](/research/urolithin-a-mitophagy-cellular-health).
Does conversion from food vary enough between people to change what a supplement does for them?
Yes. Only 12% of the 2021 group had detectable urolithin A glucuronide before any juice, and about 40% converted meaningfully after it. Blood levels after juice varied far more than levels after the 500 mg dose. The authors conclude that direct dosing overcomes differences in gut microbiome and diet. The study covered 24 hours per exposure, so it shows the first day's pattern, not long-term outcomes.
Is it worth testing your metabotype, and what would the result change?
For most people, no. A metabotype test tells you about food, and it does not change the dose used in the trials. The 2021 team validated a finger-prick method against blood levels in its own study, but we did not find a consumer test to recommend. A high-converter result would suggest food might work better for you. A low-converter result would confirm that food is unreliable. If you want a known amount either way, the decision is the same: a supplement at 500 mg, with the label checked.
What does a supplement deliver that food does not reliably deliver?
A known amount and a more predictable blood level. In the 2021 study, the 500 mg dose produced more uniform levels across the group than juice did, and over 24 hours it delivered more than six times the total exposure of the juice. Food also brings other compounds that a capsule does not, and the 2021 study did not test those. The [urolithin A ingredient guide](/ingredients/urolithin-a) covers the forms and doses on the market.
What is still unknown about metabotypes and long-term outcomes?
Quite a lot. The 2014 letter says a link between metabotype and health benefit or illness risk deserves further research, and the 2018 cohort calls its health consequences potential. We did not find a study showing that knowing your metabotype changes long-term outcomes. The human trials cited here ran four months at most, so none of them speaks to years of use. Until more data arrive, treat metabotype as a biology question, not a diagnosis.